Glaxo Settles Patent Suit Over Paxil

Law360, New York (January 2, 2004, 12:00 AM EST) -- GlaxoSmithKline settled a lawsuit against Synthon Pharmaceuticals, clearing the way for generic drug maker to immediately start selling Pexeva, its competitor to the U.K. pharmaceutical giant’s antidepressant Paxil.

A separate case pending before the U.S. Patent and Trademark Office will determine whether Synthon must pay GSK royalties on Pexeva sales.

Glaxo had sued Synthon for patent infringement in the U.S. District Court for the North Carolina Middle District on Nov. 22, 2000, and the two-week trial had been scheduled for Jan. 12.

Paxil is one of...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.